Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Hoth Therapeutics, Inc. entered into Purchase Agreement with an accredited investor valued at aggregate gross proceeds of approximately $10 million (effective 2022-12-29).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- an accredited investor
- Value
- aggregate gross proceeds of approximately $10 million
- Effective
- 2022-12-29
Exact text from the filing
On December 29, 2022, Hoth Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited investor (the “Investor”) pursuant to which it agreed to sell an aggregate of (i) 140,000 shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), (ii) warrants (the “Pre-Funded Warrants”) to purchase up to 1,860,000 shares (the “Pre-funded Warrant Shares”) of Common Stock and (iii) warrants (the “Common Stock Warrants” and together with the Pre-Funded Warrants, the “Warrants”) to purchase up to 2,500,000 shares (the “Warrant Shares” and together with the Shares and the Pre-Funded Warrant Shares, the “Registrable Securities”) of Common Stock at a purchase price of $5.00 per share and accompanying warrant (less $0.001 for each Pre-Funded Warrant and accompanying warrant) in a private placement for aggregate gross proceeds of approximately $10 million, exclusive of placement agent commission and fees and o
View on SEC.gov